Merckâ€™s third-quarter earnings call highlighted strong performance, with significant growth in both revenue and earnings-per-share, driven by new product launches like Gardasil, Januvia, and Isentress. However, the company faced challenges from currency fluctuations, the financial implications of NovaCardia acquisition, and ongoing legal costs related to VIOXX litigation, which might temper the immediate stock price reaction. Despite these, the positive revenue guidance update and future growth prospects from new products are likely to have a positive short-term impact on the stock.
[1]